Gene: FLT3 ×
Source: INFERRED ×
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913487
rs121913487
FLT3
C 0.800 CausalMutation CLINVAR FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. 15374878

2005
dbSNP: rs121913487
rs121913487
FLT3
C 0.800 CausalMutation CLINVAR Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. 15256420

2004
dbSNP: rs121913487
rs121913487
FLT3
T 0.800 CausalMutation CLINVAR Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. 15256420

2004
dbSNP: rs121913487
rs121913487
FLT3
T 0.800 CausalMutation CLINVAR Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. 11290608

2001
dbSNP: rs121913487
rs121913487
FLT3
C 0.800 CausalMutation CLINVAR Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. 11290608

2001
dbSNP: rs121913488
rs121913488
FLT3
A 0.740 CausalMutation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014
dbSNP: rs121913488
rs121913488
FLT3
G 0.740 CausalMutation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014
dbSNP: rs121913488
rs121913488
FLT3
T 0.740 CausalMutation CLINVAR The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. 23783394

2013
dbSNP: rs121913488
rs121913488
FLT3
T 0.740 CausalMutation CLINVAR The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. 23714533

2013
dbSNP: rs121913488
rs121913488
FLT3
A 0.740 CausalMutation CLINVAR Mutational landscape of AML with normal cytogenetics: biological and clinical implications. 23261068

2013
dbSNP: rs121913488
rs121913488
FLT3
T 0.740 CausalMutation CLINVAR Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. 23321257

2013
dbSNP: rs121913488
rs121913488
FLT3
G 0.740 CausalMutation CLINVAR The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. 23783394

2013
dbSNP: rs121913488
rs121913488
FLT3
T 0.740 CausalMutation CLINVAR Mutational landscape of AML with normal cytogenetics: biological and clinical implications. 23261068

2013
dbSNP: rs121913488
rs121913488
FLT3
G 0.740 CausalMutation CLINVAR Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. 23321257

2013
dbSNP: rs121913488
rs121913488
FLT3
A 0.740 CausalMutation CLINVAR The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. 23783394

2013
dbSNP: rs121913488
rs121913488
FLT3
G 0.740 CausalMutation CLINVAR In addition, crenolanib inhibited drug-resistant AML primary blasts with FLT3-ITD and D835H/Y mutations. 24046014

2013
dbSNP: rs121913488
rs121913488
FLT3
G 0.740 CausalMutation CLINVAR The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. 23714533

2013
dbSNP: rs121913488
rs121913488
FLT3
A 0.740 CausalMutation CLINVAR Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. 23430109

2013
dbSNP: rs121913488
rs121913488
FLT3
G 0.740 CausalMutation CLINVAR Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. 23430109

2013
dbSNP: rs121913488
rs121913488
FLT3
A 0.740 CausalMutation CLINVAR The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. 23714533

2013
dbSNP: rs121913488
rs121913488
FLT3
A 0.740 CausalMutation CLINVAR Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. 23321257

2013
dbSNP: rs121913488
rs121913488
FLT3
T 0.740 CausalMutation CLINVAR Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. 23430109

2013
dbSNP: rs121913488
rs121913488
FLT3
G 0.740 CausalMutation CLINVAR Mutational landscape of AML with normal cytogenetics: biological and clinical implications. 23261068

2013
dbSNP: rs121913488
rs121913488
FLT3
A 0.740 CausalMutation CLINVAR Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. 22368270

2012
dbSNP: rs121913488
rs121913488
FLT3
T 0.740 CausalMutation CLINVAR Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. 22368270

2012